Bank of America’s Ligand Pharmaceuticals LGND Stock Holding History

Bank of America’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-12,503	Closed	-$813K	–	7067
2019 Q4	$813K	Buy	+12,503	New	+$836K	﹤0.01%	4639
2019 Q1	–	Sell	-8,015	Closed	-$679K	–	7271
2018 Q4	$679K	Buy	+8,015	New	+$854K	﹤0.01%	4715
2016 Q3	–	Sell	-40,075	Closed	-$2.98M	–	7239
2016 Q2	$2.98M	Hold	40,075	–	–	﹤0.01%	3273
2016 Q1	$2.68M	Buy	+40,075	New	+$2.44M	﹤0.01%	3319
2014 Q4	–	Sell	-11,381	Closed	-$334K	–	7828
2014 Q3	$334K	Sell	11,381 -24,045	-68%	-$798K	﹤0.01%	4938
2014 Q2	$1.38M	Buy	35,426 +15,388	+77%	+$624K	﹤0.01%	3717
2014 Q1	$841K	Sell	20,038 -801	-4%	-$33.4K	﹤0.01%	4088
2013 Q4	$684K	Sell	20,839 -3,366	-14%	-$110K	﹤0.01%	4469
2013 Q3	$654K	Buy	24,205 +9,618	+66%	+$271K	﹤0.01%	4375
2013 Q2	$340K	Buy	+14,587	New	+$262K	﹤0.01%	5120

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Bank of America's LGND Position: Q1 2026 in Review

Bank of America increased its Ligand Pharmaceuticals (LGND) stake by 31% in Q1 2026, buying an estimated $7.46M and bringing the position to 157,865 shares worth $31.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2001.

Bank of America first reported a position in LGND in Q2 2013 and has held it in 52 quarters since. The position peaked at $129M in Q3 2017. 358 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

Bank of America held 157,865 shares of Ligand Pharmaceuticals worth $31.5M as of Q1 2026.
Bank of America bought 37,696 Ligand Pharmaceuticals shares in Q1 2026, an estimated $7.46M.
Ligand Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2001 holding.
Bank of America first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Bank of America's Ligand Pharmaceuticals position peaked at $129M in Q3 2017.
358 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.